Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla
One of the first pharma victims of the current partial shutdown of the US government has emerged after the FDA said it would delay a review of a peanut allergy drug from Aimmune Therapeutic
